Overview
Extrarenal rhabdoid tumors are aggressive malignancies characterized by SMARCB1/INI1 gene inactivation, typically occurring in children but can arise from various extrarenal sites. These tumors are associated with poor prognosis, though patients with rhabdoid tumor predisposition syndrome (RTPS) may exhibit better outcomes with intensive treatment. 1Diagnosis
Genetic testing for truncating heterozygous SMARCB1/INI1 mutations.
Histopathological examination confirming rhabdoid morphology.
Imaging studies (MRI, CT) to determine tumor location and extent.
Biopsy for definitive diagnosis and molecular characterization. 1Management
First-line treatment: Multi-modality therapy including surgery, chemotherapy, and radiation (when indicated).
Chemotherapy regimens: Specific regimens recommended by organizations like the EU-RHAB registry.
Radiotherapy: Consideration based on tumor location and extent, though some patients may be treated without radiotherapy. 1Special Populations
Pediatrics: Intensive treatment with curative intent is justified, even in cases of RTPS. 1Key Recommendations
Intensive multi-modality treatment with curative intent should be administered to children with extrarenal rhabdoid tumors, including those with RTPS. (Evidence: Strong 1)
Consideration of radiotherapy should be individualized based on tumor characteristics and patient factors, as some patients may achieve favorable outcomes without radiotherapy. (Evidence: Moderate 1)References
1 Kordes U, Bartelheim K, Modena P, Massimino M, Biassoni V, Reinhard H et al.. Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). Pediatric blood & cancer 2014. link